日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

舒尼替尼相关性高血压和中性粒细胞减少症作为转移性肾细胞癌患者的疗效生物标志物

Donskov, Frede; Michaelson, M Dror; Puzanov, Igor; Davis, Mellar P; Bjarnason, Georg A; Motzer, Robert J; Goldstein, David; Lin, Xun; Cohen, Darrel P; Wiltshire, Robin; Rini, Brian I

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

对伊马替尼治疗失败后胃肠道间质瘤患者的舒尼替尼随机、安慰剂对照 III 期试验进行完整的纵向分析

Demetri George D, Garrett Christopher R, Schöffski Patrick, Shah Manisha H, Verweij Jaap, Leyvraz Serge, Hurwitz Herbert I, Pousa Antonio Lopez, Le Cesne Axel, Goldstein David, Paz-Ares Luis, Blay Jean-Yves, McArthur Grant A, Xu Qiang Casey, Huang Xin, Harmon Charles S, Tassell Vanessa, Cohen Darrel P, Casali Paolo G

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

原发性和继发性激酶基因型与舒尼替尼在伊马替尼耐药性胃肠道间质瘤中的生物学和临床活性相关。

Heinrich, Michael C; Maki, Robert G; Corless, Christopher L; Antonescu, Cristina R; Harlow, Amy; Griffith, Diana; Town, Ajia; McKinley, Arin; Ou, Wen-Bin; Fletcher, Jonathan A; Fletcher, Christopher D M; Huang, Xin; Cohen, Darrel P; Baum, Charles M; Demetri, George D